IV administration of endothelin B receptor drug reduces memory loss, oxidative stress in Alzheimer’s disease

4 septiembre 2015

An estimated 5.3 million people in the U.S. suffer from Alzheimer’s disease (AD). The five current FDA-approved AD medications only help mask the disease symptoms instead of treating the underlying disease. In a new study, researchers used IRL-1620, a chemical that binds to endothelin B receptors, to treat AD in rats.
http://www.sciencedaily.com/releases/2015/09/150904144606.htm